Dr. Richard Gordon leads the Translational Neuroscience Laboratory at The University of Queensland in Brisbane, Australia. His research program aims at understanding how chronic inflammation and microbiome dysfunction are initiated in Parkinson’s disease (PD) and how they contribute to disease progression. His group works on identifying new therapeutic targets and treatment strategies to slow or halt the progression of PD. Dr. Gordon’s research has contributed to groundbreaking advances in his field, including most recently, the discovery of inflammasome activation in PD as a driver of synuclein pathology and disease progression. His team is also studying inflammasome activation pathways as biomarkers for PD. Dr. Gordon is a certified toxicologist with the American Board of Toxicology (ABT) and has served as a member of the Gene Technology Technical Advisory Committee for the Australian Federal Government. He is also a Science Ambassador for the World Parkinson Coalition.